Free Trial
NASDAQ:KLRS

Allovir (KLRS) Stock Price, News & Analysis

$2.91 +0.12 (+4.30%)
As of 04:00 PM Eastern

About Allovir Stock (NASDAQ:KLRS)

Key Stats

Today's Range
$2.79
$2.94
50-Day Range
N/A
52-Week Range
$2.64
$24.15
Volume
39,617 shs
Average Volume
38,453 shs
Market Capitalization
$54.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Receive KLRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allovir and its competitors with MarketBeat's FREE daily newsletter.

KLRS Stock News Headlines

Allovir (NASDAQ:KLRS) Downgraded to Sell Rating by Wall Street Zen
See More Headlines

KLRS Stock Analysis - Frequently Asked Questions

Allovir's stock was trading at $2.79 on January 1st, 2025. Since then, KLRS stock has increased by 4.7% and is now trading at $2.92.
View the best growth stocks for 2025 here
.

Shares of KLRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological Products, Except Diagnostic Substances
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KLRS
Web
N/A
Fax
N/A
Employees
110
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$52.18 million
Optionable
N/A
Beta
0.70
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:KLRS) was last updated on 5/27/2025 by MarketBeat.com Staff
From Our Partners